Phase II, randomized, open, controlled study of AS03-adjuvanted H5N1 pre-pandemic influenza vaccine in children aged 3 to 9 years: Follow-up of safety and immunogenicity persistence at 24 months post-vaccination

Influenza and other Respiratory Viruses

Volumn 9, Issue 2, 2015, Pages 68-77

  Díez Domingo, Javier ^a   Baldó, José María ^b   Planelles Catarino, Maria Victoria ^b   Garcés Sánchez, María ^b   Ubeda, Isabel ^b   Jubert Rosich, Angels ^b   Marès, Josep ^c   Garcia Corbeira, Pilar ^d   Moris, Philippe ^e   Teko, Maurice ^f   Vanden Abeele, Carline ^e   Gillard, Paul ^e  

^a Centre of Public Health Research   (Spain)

^b Centro de Salud Nazaret   (Spain)

^c Institut Pediatric Mares Riera   (Spain)

^d GSK   (Spain)

^e GSK   (Belgium)

^f Clinics   (Belgium)

Author keywords

AS03 adjuvanted; Cell mediated immunity; Children; H5N1 influenza vaccine; Pre pandemic

Indexed keywords

AMINOTRANSFERASE; AS03 A ADJUVANT; AS03 B ADJUVANT; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; UNCLASSIFIED DRUG; ALPHA TOCOPHEROL; ASO3B ADJUVANT; DRUG COMBINATION; INFLUENZA VIRUS HEMAGGLUTININ; POLYSORBATE; SQUALENE; VIRUS ANTIBODY;

ADJUVANT THERAPY; AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; AUTOIMMUNE HEPATITIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHILD; CONTROLLED STUDY; CROSS REACTION; DISEASE SEVERITY; DRUG SAFETY; FEMALE; FOLLOW UP; GASTROENTERITIS; HEMAGGLUTINATION INHIBITION; HUMAN; IMMUNOGENICITY; INFLUENZA; INFLUENZA VACCINATION; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MULTICENTER STUDY; NORMAL HUMAN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; UVEITIS; VITILIGO; WOUND; BLOOD; CLINICAL TRIAL; DRUG COMBINATION; HEMAGGLUTINATION INHIBITION TEST; IMMUNOLOGY; INFANT; INFLUENZA A VIRUS (H5N1); INFLUENZA, HUMAN; PRESCHOOL CHILD; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ALPHA-TOCOPHEROL; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; DRUG COMBINATIONS; FEMALE; FOLLOW-UP STUDIES; HEMAGGLUTINATION INHIBITION TESTS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; IMMUNITY, CELLULAR; INFANT; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; POLYSORBATES; SQUALENE; VACCINATION;

EID: 84923466440     PISSN: 17502640     EISSN: 17502659     Source Type: Journal    
DOI: 10.1111/irv.12295     Document Type: Article

References (21)

1. Basta NE, Chao DL, Halloran ME, Matrajt L, Longini IM Jr. Strategies for pandemic and seasonal influenza vaccination of schoolchildren in the United States. Am J Epidemiol 2009; 170:679-686.
2. Jennings LC, Monto AS, Chan PK, Szucs TD, Nicholson KG. Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans. Lancet Infect Dis 2008; 8:650-658.
3. Food and Drug Administration. FDA approves first adjuvanted vaccine for prevention of H5N1 avian influenza. Nov. 22, 2013; Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm376444.htm. [Accessed 5 June 2014].
4. US Food and Drug Administration. H5N1 Influenza Virus Vaccine, manufactured by Sanofi Pasteur, Inc. Questions and Answers. 2013; Available at: http://www.fda.gov/BiologicsBloodVaccines/Vaccines/QuestionsaboutVaccines/ucm080753.htm. [Accessed 5 June 2014].
5. World Health Organization. Use of licensed H5N1 influenza vaccines in the interpandemic period. 2009. Available at: http://www.who.int/immunization/sage/SAGE_H5N1_26Mayb.pdf [Accessed 5 June 2014].
6. Leroux-Roels G. Prepandemic H5N1 influenza vaccine adjuvanted with AS03: a review of the pre-clinical and clinical data. Expert Opin Biol Ther 2009; 9:1057-1071.
7. Díez-Domingo J, Garcés-Sanchez M, Baldó J-M et al. Immunogenicity and safety of H5N1 A/Vietnam/1194/2004 (clade 1) AS03-adjuvanted pre-pandemic candidate influenza vaccines in children aged 3 to 9 years: a Phase II, randomized, open, controlled study. Pediatr Infect Dis J 2010; 29:e35-e46.
8. Stephenson I, Wood JM, Nicholson KG, Charlett A, Zambon MC. Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine. Virus Res 2004; 103:91-95.
9. Maecker H, Maino V, Picker L. Immunofluorescence analysis of T-Cell responses in health and disease. J Clin Immunol 2000; 20:391-399.
10. Waldrop S, Davis K, Maino V, Picker L. Normal human CD4+ memory T cells display broad heterogeneity in their activation threshold for cytokine synthesis. J Immunol 1998; 161:5284-5295.
11. European Medicines Agency. Recommendations for the Pharmacovigilance Plan as part of the Risk Management Plan to be submitted with the Marketing Authorization Application for a Pandemic Influenza Vaccine (Revision 1.1, EMEA/359381/2009). Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Report/2010/01/WC500051739.pdf [Accessed 5 June 2014].
12. Barker CI, Snape MD. Pandemic influenza A H1N1 vaccines and narcolepsy: vaccine safety surveillance in action. Lancet Infect Dis 2014; 14:227-238.
13. Han F, Lin L, Warby SC et al. Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China. Ann Neurol 2011; 70:410-417.
14. Doherty PC, Turner SJ, Webby RG, Thomas PG. Influenza and the challenge for immunology. Nat Immunol 2006; 7:449-455.
15. Swain SL, Agrewala JN, Brown DM et al. CD4+ T-cell memory: generation and multi-faceted roles for CD4+ T cells in protective immunity to influenza. Immunol Rev 2006; 211:8-22.
16. McKinstry KK, Strutt TM, Kuang Y et al. Memory CD4+ T cells protect against influenza through multiple synergizing mechanisms. J Clin Invest 2012; 122:2847-2856.
17. Teijaro JR, Turner D, Pham Q, Wherry EJ, Lefrancois L, Farber DL. Cutting edge: tissue-retentive lung memory CD4 T cells mediate optimal protection to respiratory virus infection. J Immunol 2011; 187:5510-5514.
18. Wilkinson TM, Li CK, Chui CS et al. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med 2012; 18:274-280.
19. Wagar LE, Gentleman B, Pircher H, McElhaney JE, Watts TH. Influenza-specific T cells from older people are enriched in the late effector subset and their presence inversely correlates with vaccine response. PLoS ONE 2011; 6:e23698.
20. Moris P, van der Most R, Leroux-Roels I et al. H5N1 influenza vaccine formulated with AS03 A induces strong cross-reactive and polyfunctional CD4 T-cell responses. J Clin Immunol 2011; 31:443-454.
21. Nurieva RI, Chung Y, Hwang D et al. Generation of T follicular helper cells is mediated by interleukin-21 but independent of T helper 1, 2, or 17 cell lineages. Immunity 2008; 29:138-149.